41,904 results match your criteria myeloma cell


Retrospective study of treatment patterns and outcomes post-lenalidomide for multiple myeloma in Canada.

Eur J Haematol 2021 Jun 15. Epub 2021 Jun 15.

Cross Cancer Institute, University of Alberta, Canada.

Lenalidomide is an important component of initial therapy in newly-diagnosed multiple myeloma, either as maintenance therapy post-autologous stem cell transplantation (ASCT) or as first-line therapy with dexamethasone for patients' ineligible for ASCT (non-ASCT). This retrospective study investigated treatment patterns and outcomes for ASCT-eligible and -ineligible patients who relapsed after lenalidomide as part of first-line therapy, based on data from the Canadian Myeloma Research Group Database for patients treated between January 2007 and April 2019. Among 256 patients who progressed on lenalidomide maintenance therapy, 28. Read More

View Article and Full-Text PDF

Detecting FRET in living cells by conventional and spectral flow cytometry.

Cytometry A 2021 Jun 14. Epub 2021 Jun 14.

Department of Lymphoma and Myeloma, The University of Texas-MD Anderson Cancer Center, Houston, TX, USA.

Assays based on Förster resonance energy transfer (FRET) can be used to study many processes in cell biology. Although this is most often done with microscopy for fluorescence detection, we report two ways to measure FRET in living cells by flow cytometry. Using a conventional flow cytometer and the "3-cube method" for intensity-based calculation of FRET efficiency, we measured the enzymatic activity of specific kinases in cells expressing a genetically-encoded reporter. Read More

View Article and Full-Text PDF

Inhibition of translation initiation factor eIF4a inactivates heat shock factor 1 (HSF1) and exerts anti-leukemia activity in AML.

Leukemia 2021 Jun 14. Epub 2021 Jun 14.

Department of Leukemia, Section of Molecular Hematology and Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Eukaryotic initiation factor 4A (eIF4A), the enzymatic core of the eIF4F complex essential for translation initiation, plays a key role in the oncogenic reprogramming of protein synthesis, and thus is a putative therapeutic target in cancer. As important component of its anticancer activity, inhibition of translation initiation can alleviate oncogenic activation of HSF1, a stress-inducible transcription factor that enables cancer cell growth and survival. Here, we show that primary acute myeloid leukemia (AML) cells exhibit the highest transcript levels of eIF4A1 compared to other cancer types. Read More

View Article and Full-Text PDF

Palliative Radiotherapy for Diffuse Large B-cell Lymphoma.

Clin Lymphoma Myeloma Leuk 2021 May 19. Epub 2021 May 19.

Department of Radiation Oncology, University of Pennsylvania, Philadelphia, PA, USA.

Recent improvements in chemoimmunotherapies, targeted agents, hematopoietic stem cell transplants, and cellular therapies have revolutionized treatment paradigms for patients with diffuse large B-cell lymphoma (DLBCL). Even in the relapsed or refractory setting, contemporary treatment options are delivered with curative intent and can lead to lasting remissions. Although such therapies have improved overall outcomes, they have increasingly led to a wide variety of presentations of recurrent tumors in need of palliation. Read More

View Article and Full-Text PDF

Body mass index and survival of patients with lymphoma.

Leuk Lymphoma 2021 Jun 14:1-8. Epub 2021 Jun 14.

Department of Health and Human Services, Radiation Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.

The impact of body mass index (BMI) on survival in lymphoma remains controversial. We leveraged a prospective cohort of lymphoma patients enrolled to SPORE Molecular Epidemiology Resource between 2002 and 2015 to assess the association of BMI before diagnosis, BMI at diagnosis, and BMI change over time with lymphoma-specific survival (LSS). A total of 4009 lymphoma patients (670 diffuse large B-cell lymphoma (DLBCL), 689 follicular lymphoma (FL), 1018 chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), and 1632 other subtypes) were included. Read More

View Article and Full-Text PDF

Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens.

Leuk Lymphoma 2021 Jun 14:1-10. Epub 2021 Jun 14.

Department of Clinical Hematology and Cell Therapy, University Hospital, Limoges, France.

We aimed to compare real-world outcomes, resource use, and costs for patients with newly diagnosed multiple myeloma (NDMM) treated with continuous first-line (1 L) lenalidomide or fixed bortezomib in Europe. We performed a multicenter, retrospective, observational chart review of transplant-ineligible NDMM patients across 7 countries. Of 453 eligible patients, 220 received 1 L lenalidomide-based regimens; 105 (47. Read More

View Article and Full-Text PDF

Exosomal circRNA as a novel potential therapeutic target for multiple myeloma-related myocardial damage.

Cancer Cell Int 2021 Jun 13;21(1):311. Epub 2021 Jun 13.

Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, 16369 Jingshi Road, Jinan, 250014, China.

Introduction: Myocardial damage is a mostly incurable complication of multiple myeloma (MM) that seriously affects the treatment outcome and quality of life of patients. Exosomal circular RNAs (exo-circRNAs) play an important role in tumor occurrence and development and are considered key factors in MM pathogenesis. However, the role and mechanism of action of exo-circRNAs in MM-related myocardial damage are still unclear. Read More

View Article and Full-Text PDF

Co-existence of multiple myeloma and perivascular endothelial cell tumor.

Int J Lab Hematol 2021 Jun 12. Epub 2021 Jun 12.

Laboratory Medicine Program, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada.

View Article and Full-Text PDF

The immunity-malignancy equilibrium in multiple myeloma: lessons from oncogenic events in plasma cells.

FEBS J 2021 Jun 12. Epub 2021 Jun 12.

Age related Diseases Unit, Division of Genetics and Cell Biology, San Raffaele Scientific Institute, Milano, Italy.

Multiple myeloma is a malignancy of plasma cells that grow within the bone marrow and maintain massive immunoglobulin production. Disease evolution is driven by genetic lesions, whose effects on cell biology and fitness underlie addictions and vulnerabilities of myeloma cells. Several genes mutated in myeloma are strictly involved in dictating plasma cell identity and antibody factory function. Read More

View Article and Full-Text PDF

IMiDs uniquely synergize with TKIs to upregulate apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells expressing a dominant-negative IKZF1 isoform.

Cell Death Discov 2021 Jun 11;7(1):139. Epub 2021 Jun 11.

Department of Pediatrics, Graduate School of Medicine, University of Yamanashi, Chuo, Yamanashi, Japan.

The long-term prognosis of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL) is still unsatisfactory even after the emergence of tyrosine kinase inhibitors (TKIs) against chimeric BCR-ABL, and this is associated with the high incidence of genetic alterations of Ikaros family zinc finger 1 (IKZF1), most frequently the hemi-allelic loss of exons 4-7 expressing a dominant-negative isoform Ik6. We found that lenalidomide (LEN), a representative of immunomodulatory drugs (IMiDs), which have been long used for the treatment of multiple myeloma, specifically induced accumulation of Ik6 with the disappearance of functional isoforms within 24 h (i.e. Read More

View Article and Full-Text PDF

Taking therapeutic apheresis services to patients in South Africa: An eight year review of SANBS mobile therapeutic apheresis service, 2013-2020.

Transfus Apher Sci 2021 May 21:103167. Epub 2021 May 21.

Sanquin Blood Supply, The Netherlands.

Introduction: A 20 year review of health and health care presents the multiple challenges faced by South Africans. Health and poverty is highlighted with 45% of population living on approximately US$ 2 per day and 10 million living on less than US$ 1 per day. Widening disparities in health care provision between public and private sector hospital services exist. Read More

View Article and Full-Text PDF

Cereblon Enhancer Methylation and IMiD Resistance in Multiple Myeloma.

Blood 2021 Jun 11. Epub 2021 Jun 11.

University Hospital Würzburg, Würzburg, Germany.

Cereblon is the direct binding target of the immunomodulatory drugs that are commonly used to treat Multiple Myeloma, the second most frequent hematologic malignancy. Patients respond well to initial IMiD treatment but virtually all develop drug resistance over time with the underlying mechanisms poorly understood. We identified a yet undescribed DNA hypermethylation in an active intronic CRBN enhancer. Read More

View Article and Full-Text PDF

Venetoclax for the Treatment of Multiple Myeloma: Outcomes Outside of Clinical Trials.

Am J Hematol 2021 Jun 11. Epub 2021 Jun 11.

Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester.

Introduction: Multiple myeloma (MM) remains an incurable disease despite incorporation of novel agents. Venetoclax, a B-cell lymphoma 2 (BCL-2) inhibitor is approved for some hematologic malignancies but not yet for MM, although clinical trials have shown efficacy in patients with MM particularly those harboring t(11;14).

Methods: We reviewed the medical records of relapsed and/or refractory MM patients to study the efficacy and safety of venetoclax used outside of clinical trials at Mayo Clinic between December 2016 and March 2019. Read More

View Article and Full-Text PDF

Δ133p53α enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity.

J Immunother Cancer 2021 Jun;9(6)

Department of Hematology, Oncology and Pneumology, University Medical Centre of the Johannes Gutenberg University Mainz, Mainz, Germany

Background: Tumor microenvironment-associated T cell senescence is a key limiting factor for durable effective cancer immunotherapy. A few studies have demonstrated the critical role of the tumor suppressor TP53-derived p53 isoforms in cellular senescence process of non-immune cells. However, their role in lymphocytes, in particular tumor-antigen (TA) specific T cells remain largely unexplored. Read More

View Article and Full-Text PDF

Inhibition of Pim-2 kinase by LT-171-861 promotes DNA damage and exhibits enhanced lethal effects with PARP inhibitor in multiple myeloma.

Biochem Pharmacol 2021 Jun 7;190:114648. Epub 2021 Jun 7.

State Key Laboratory of Natural Medicines, Jiangsu Key Laboratory of Carcinogenesis and Intervention, Department of Physiology, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, People's Republic of China. Electronic address:

Multiple myeloma (MM) is a malignancy of antibody-producing plasma cells with genomic instability and genetic abnormality as its two hallmarks. Therefore, DNA damage is pervasive in MM cells, which indicates irregular DNA damage response (DDR) pathway. In this study, we demonstrated that LT-171-861, a multiple kinase inhibitor, could inhibit proliferation and induce apoptosis in MM cells. Read More

View Article and Full-Text PDF

Allogeneic Stem Cell Transplantation in Patients with High-Risk Multiple Myeloma: Utopia or Continuous Challenge in Aiming for Cure?

Curr Treat Options Oncol 2021 Jun 10;22(8):65. Epub 2021 Jun 10.

Adults Hematology and Stem Cell Transplantation Department, King Fahad Specialist Hospital, 31444, Dammam, Kingdom of Saudi Arabia.

Opinion Statement: Nowadays, several novel agents have been introduced in the treatment of multiple myeloma, not only resulting in high response rates and prolonged survival but also offering good quality of life. However, the potential of cure, especially for patients with advanced or unfavorable disease features, remains elusive. Allogeneic hematopoietic stem cell transplantation, based mainly on the graft vs. Read More

View Article and Full-Text PDF

Novel Non-coding RNA Analysis in Multiple Myeloma Identified Through High-Throughput Sequencing.

Front Genet 2021 24;12:625019. Epub 2021 May 24.

Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.

This study aimed to explore the potential effects of novel non-coding ribose nucleic acids (ncRNAs) in patients with multiple myeloma (MM). The gene expression profile of plasma cells was used for sequence analysis to explore the expression pattern of ncRNAs in MM. The expression patterns of non-coding RNAs in MM were analyzed by RNA sequencing (whole-transcriptome-specific RNA sequencing). Read More

View Article and Full-Text PDF

[Current status and future prospects of immunotherapy for multiple myeloma].

Authors:
Yoichi Imai

Rinsho Ketsueki 2021 ;62(5):407-417

IMSUT Hospital, The Institute of Medical Science, The University of Tokyo.

The introduction of autologous stem cell transplantation, proteasome inhibitors, and immunomodulatory drugs (IMiDs) has improved the treatment outcome for multiple myeloma (MM). However, many patients develop resistance to existing therapies, and novel treatment strategies for these patients must be established. Therapeutic antibodies including daratumumab targeting CD38 and elotuzumab targeting SLAMF7 have been introduced in the clinic as immunotherapies for MM. Read More

View Article and Full-Text PDF

1,3-Butadiene, styrene and lymphohaematopoietic cancers among North American synthetic rubber polymer workers: exposure-response analyses.

Occup Environ Med 2021 Jun 9. Epub 2021 Jun 9.

Epidemiology, The University of Alabama at Birmingham School of Public Health, Birmingham, Alabama, USA.

Objective: To evaluate exposure-response between 1,3-butadiene, styrene and lymphohaematopoietic cancers in an updated cohort of workers at six North American plants that made synthetic rubber polymers.

Methods: Employees were followed from 1943 through 2009 to determine mortality outcomes. Cox regression analyses estimated rate ratios (RRs) and 95% CIs by quartile of cumulative exposure to butadiene or styrene, measured in parts per million-years (ppm-years), and exposure-response trends for all leukaemia, lymphoid leukaemia, myeloid leukaemia, acute myeloid leukaemia, non-Hodgkin's lymphoma (NHL), multiple myeloma and all B-cell malignancies. Read More

View Article and Full-Text PDF

CAR-T therapy alters synthesis of platelet-activating factor in multiple myeloma patients.

J Hematol Oncol 2021 Jun 9;14(1):90. Epub 2021 Jun 9.

School of Medicine and Holistic Integrative Medicine, Nanjing University of Chinese Medicine, 138 Xianlin Road, Nanjing, 210023, China.

The chimera antigen receptor (CAR) T cell therapy is a novel and potential targeted therapy and has achieved satisfactory efficacy in patients with relapsed or refractory multiple myeloma (MM) in recent years. However, cytokine release syndrome (CRS) and clinical efficacy have become the major obstacles which limit the application of CAR-T in clinics. To explore the potential biomarkers in plasma for evaluating CRS and clinical efficacy, we performed metabolomic and lipidomic profiling of plasma samples from 17 relapsed or refractory MM patients received CAR-T therapy. Read More

View Article and Full-Text PDF

The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma.

Transplant Cell Ther 2021 Jun 6. Epub 2021 Jun 6.

Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

The fifth annual Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma was conducted as one of the American Society of Hematology Annual Meeting Scientific Workshops on Thursday December 3, 2020. This workshop focused on four main topics: 1) integrating MRD into clinical trial design and practice; 2) the molecular and immuno-biology of disease evolution and progression in myeloma; 3) adaptation of next generation sequencing, next generation flow cytometry and CyTOF techniques; and 4) chimeric antigen receptor T-cell and other cellular therapies for myeloma. In this report, we provide a summary of the workshop presentations and discuss future directions in the field. Read More

View Article and Full-Text PDF

Development of a method for the determination of the JAK2 gene mRNA in venous blood and assessment of its diagnostic value in oncohematology.

Klin Lab Diagn 2021 06;66(6):379-384

Krasnoyarsk branch of the «National Research Center for Hematology» Department of Health.

Overactive JAK pathway signaling is a hallmark of immune diseases and critically affects on inflammation and coagulation. A number of mutations in the JAK2 gene act as driving forces of myeloproliferative neoplasms (MPN), the pathogenesis of certain variants of acute leukemia, a number of solid malignancies and cardiovascular diseases. Assays for quantifying JAK2 mRNA in circulating blood cells can be used as a marker associated with the activity of this enzyme. Read More

View Article and Full-Text PDF

JAK2 Rearrangements Are a Recurrent Alteration in CD30+ Systemic T-Cell Lymphomas With Anaplastic Morphology.

Am J Surg Pathol 2021 Jul;45(7):895-904

Department of Pathology, Massachusetts General Hospital, Harvard Medical School.

Peripheral T-cell lymphoma (PTCL) comprises a heterogenous group of rare mature T-cell neoplasms. While some PTCL subtypes are well-characterized by histology, immunophenotype, and recurrent molecular alterations, others remain incompletely defined. In particular, the distinction between CD30+ PTCL, not otherwise specified and anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma can be subject to disagreement. Read More

View Article and Full-Text PDF

[Research Advance of Immune Checkpoint Molecule TIGIT in Hematological Malignancies--Review].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):993-997

Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430020, Hubei Province, China,E-mail:

TIGIT is an inhibitory receptor containing T cell immunoglobulin and immune receptor protein tyrosine inhibitory motif domain. It shows high expression level on the surface of immune cells in tumor patients and plays an inhibitory role by binding to corresponding ligands, CD155 and CD112. Studying the mechanism of inhibitory effect of TIGIT and the way to block it shows a great significance in the immunotherapy of tumor. Read More

View Article and Full-Text PDF

[Prognostic Significance of CD27 and CD56 on Newly Diagnosed MM Patients Treated with Bortezomib].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):827-831

Department of Hematology, Shengjing Hospital of China Medical University, Shenyang 110021, Liaoning Province, China,E-mail:

Objective: To investigate the significance of CD27 and CD56 in the prognosis of multiple myeloma (MM) patients, and to establish a simple and convenient prognostic risk score.

Methods: One hundred and eleven newly diagnosed MM patients treated by bortezomib in Shengjing hospital from January 1, 2013 to January 1, 2019 were selected, and the relationship between clinical characteristics and survival time of patients was analyzed.

Results: The overall survival (OS) of patients in CD27CD56 group was longer than that of patients in non-CD27CD56 group (P<0. Read More

View Article and Full-Text PDF

[The Prognosis and Predictive Value of Complement C3 in Patients with Multiple Myeloma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):819-826

Department of Hematology, Jiangdu People's Hospital of Yangzhou, Yangzhou 225000, Jiangsu Province, China,E-mail:

Objective: To investigate the effect of complement C3 on the prognosis of patients with multiple myeloma (MM), and to establish a predictive model to evaluate the overall survival.

Methods: Eighty newly diagnosed MM patients were enrolled, and clinical characteristics, such as sex, age, platelet count, white blood cell count, ISS stage, FISH, levels of kappa and lammda chain, complement C3 and C4 were retrospectively analyzed. Cox regression model was used for univariate and multivariate analysis about risk factors that affecting the prognosis of the MM patients. Read More

View Article and Full-Text PDF

[Effect of TRIM31 Gene Silencing on the Proliferation and Apoptosis of U266 Cells and Its Mechanism].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):805-811

Department of Blood Transfusion, The First Affiliated Hospital of Nanhua University, Hengyang 421001, Hunan Province, China,E-mail:

Objective: To investigate the effect of the tripartite motif containing 31 (TRIM31) gene silencing on the proliferation and apoptosis of multiple myeloma cells and its possible mechanism.

Methods: The normal bone marrow plasma cells (nPCs) were selected as control, and the mRNA and protein expression levels of TRIM31 in human multiple myeloma cell lines (U266, RPMI-8226, NCI-H929 and KMS-11) were detected by RT-qPCR and Western blot. Recombinant lentivirol vector containing shRNA-TRIM31 and its negative control were used to infect U266 cells respectively, and the mRNA expression level of TRIM31 in infected cells was detected by RT-qPCR. Read More

View Article and Full-Text PDF

[The Inhibiting Effect of Autophagy Inhibitor ROC-325 on Multiple Myeloma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):797-804

Institute of Hematology, Xuzhou Medical University; Department of Hematology, Xuzhou Medical University Affiliated Hospital, Xuzhou 221002, Jiangsu Province, China,E-mail:

Objective: To investigate the effects of autophagy inhibitor ROC-325 and its combination with bortezomib on the proliferation, apoptosis and autophagy of multiple myeloma cell lines.

Methods: Multiple myeloma cells were treated with ROC-325 at different concentration. The cell proliferation was detected by CCK-8. Read More

View Article and Full-Text PDF

[Early Diagnosis of One Multiple Myeloma Patient with Cold Agglutinin Syndrome as the Initial Presentation].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):787-790

Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan 030001, Shanxi Province, China,E-mail:

Objective: To analyze one case of multiple myeloma (MM) initially presenting cold agglutinin syndrome (CAS), so as to improve clinical understanding and screening of this disease.

Methods: The clinical data, laboratory examination, bone marrow result, diagnosis and treatment of the patient were analyzed and summarized to provide ideas and clinical experience for the early diagnosis and treatment of CAS secondary to MM.

Results: The clinical manifestations of asthenia, hemolysis, jaundice and scattered livedo reticularis were caused by CAS secondary to MM, which was different from the general Raynaud's phenomenon. Read More

View Article and Full-Text PDF

[Clinical Features and Prognostic Factors of Patients with Multiple Myeloma].

Zhongguo Shi Yan Xue Ye Xue Za Zhi 2021 Jun;29(3):772-780

Department of Hematology, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Suzhou 215006, Jiangsu Province, China,E-mail:

Objective: To summarize the clinical and Laboratory characteristics of patients with multiple myeloma (MM) and analyze the prognostic factors.

Methods: Two hundred MM patients were retrospectively analyzed for the following parameters, including peripheral blood, bone marrow morphology, cytogenetics, clinical staging, and response to the chemotherapy in order to summarize related factors affecting overall survival (OS). The prognostic factors were also analyzed. Read More

View Article and Full-Text PDF